MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/600/0.01/20.12.24

MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/600/0.01/20.12.24 Share Price

DE000ME66EG2

Market Closed - Bid/Ask 01:37:23 28/05/2024 pm IST			After market 11:30:08 pm
0.094 ^EUR	+3.30%		0.091	-3.19%

Current month	+40.00%
1 month	+37.88%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/600/0.01/20.12.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing	25/05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing	23/05	MT
Vertex to Participate in Upcoming June Investor Conferences	23/05	BU
ADDvise Group’s Axelerist Bags $1.4 Million Order for Medical, Lab Equipment	21/05	MT

More news

Quotes 5-day view

Date	Price	Change
28/24/28	0.094	+3.30%
27/24/27	0.091	+2.25%
24/24/24	0.089	+2.30%
23/24/23	0.087	+4.82%
22/24/22	0.083	-3.49%

Delayed Quote Börse Stuttgart

Last update May 28, 2024 at 01:37 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Morgan Stanley
WKN	ME66EG
ISIN	DE000ME66EG2
Date issued	02/01/2024
Strike	600 $
Maturity	20/12/2024 (206 Days)
Parity	100 : 1
Emission price	0.09 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.158 €
Lowest since issue	0.057 €
Delta	0.18x
Omega	8.150
Premium	36.52x
Gearing	45.19x
Moneyness	0.7446
Difference Strike	152.6 $
Difference Strike %	+25.44%
Spread	0.01 €
Spread %	10.42%
Theoretical value	0.0910
Implied Volatility	33.62 %
Total Loss Probability	87.83 %
Intrinsic value	0.000000
Present value	0.0910
Break even	609.88 €
Theta	-0.01x
Vega	0.01x
Rho	0x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

457 USD

Average target price

462.8 USD

Spread / Average Target

+1.28%

Consensus